American journal of cardiovascular drugs : drugs, devices, and other interventions
-
Am J Cardiovasc Drugs · Apr 2012
Multicenter StudyPrior antiplatelet use and cardiovascular outcomes in patients presenting with acute coronary syndromes.
Although antiplatelet therapy effectively reduces ischemic events, the cardiovascular (CV) outcome in some cases is still unpredictable. ⋯ PAP use identified a high-risk population across the ACS spectrum. Early coronary revascularization may improve CV outcomes in these patients.
-
Am J Cardiovasc Drugs · Apr 2012
Review Comparative StudyPrasugrel versus clopidogrel antiplatelet therapy after acute coronary syndrome: matching treatments with patients.
Antithrombotic therapy is imperative in the management of patients presenting with an acute coronary syndrome (ACS). The combination of antiplatelet therapy in conjunction with antithrombotic therapy has become the standard of care in improving the morbidity and mortality of patients with an ACS and in reducing ischemic complications of percutaneous coronary intervention. Patients with an ACS are at increased risk for a recurrent event, both in-hospital and for several months afterward. ⋯ These trials demonstrated greater inhibition of platelet aggregation and lower rates of the composite endpoint of death, non-fatal myocardial infarction, and stroke compared with clopidogrel. However, major bleeding occurred more frequently with prasugrel treatment than with clopidogrel. This review highlights the current state of evidence-based antiplatelet therapy and provides guidance on appropriate use of prasugrel in cardiovascular medicine.
-
Am J Cardiovasc Drugs · Apr 2012
Randomized Controlled Trial Multicenter StudyOne-year efficacy and safety of rosuvastatin + fenofibric acid combination therapy in patients with mixed dyslipidemia: evaluation of dose response.
Statins are the standard-of-care therapy for reducing low-density lipoprotein cholesterol (LDL-C) levels; however, combination with other lipid-modifying agents may be necessary to normalize lipid profiles in patients with mixed dyslipidemia who, in addition to high LDL-C, also have high triglycerides (TG) and low levels of high-density lipoprotein cholesterol (HDL-C). ⋯ Clinicaltrials.gov identifiers NCT00300482 and NCT00300430.